- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Linaclotide reduces symptoms for patients with chronic constipation, studies show
Linaclotide, an investigational drug for the relief of chronic constipation, appears to be effective and safe, according to the results of two phase 3 trials published in the August issue of the New England Journal of Medicine.
Linaclotide, an investigational drug for the relief of chronic constipation, appears to be effective and safe, according to the results of two phase 3 trials published in the August issue of the New England Journal of Medicine.
Two randomized, 12-week, multicenter, double-blind, parallel-group, placebo-controlled, dual-dose trials were conducted from August 20, 2008, through August 12, 2009 to assess efficacy and safety of the drug. Patients were randomly assigned to receive 145 µg or 290 µg of linaclotide or placebo administered once daily in the form of an oral capsule.
The primary end point of each trial was defined as including 3 or more complete spontaneous bowel movements (CSBMs) per week and an increase of at least 1 CSBM per week from baseline for at least 9 of the 12-week treatment period. Secondary end points included stool frequency (weekly rates of CSBMs and SBMs), stool consistency, severity of straining, abdominal discomfort, bloating, and constipation severity.
The primary end point was reached by 21.2% of patients in Trial 303 and 16% of patients in trial 01 who received the 145-µg dose of linaclotide and 19.4% (Trial 303), and 21.3% (Trial 01) of the patients who received the 290-µg dose of linaclotide. Of patients receiving placebo, 3.3% (Trial 303) and 6% (Trial 01) achieved primary end points (P<.01 for each linaclotide dose, as compared with placebo, for each trial). Patients who received linaclotide had significant improvements in all secondary end points from baseline to week 12 compared with patients receiving placebo. Researchers also noted significant improvements in the overall and component PAC-QOL scores for patients on both linaclotide doses compared with placebo (with the exception of psychosocial discomfort in Trial 303 for patients given the 290-µg dose).
The most common adverse event was diarrhea, which led to discontinuation of treatment by 4.7% and 3.8% of patients who received 145 µg and 290 µg of linaclotide, respectively, vs 0.5% in the placebo group.
“In these two, large phase 3 trials involving patients with chronic constipation, linaclotide led to improvement in bowel and abdominal symptoms and reduced the severity of constipation. Linaclotide has the potential to offer multisymptom relief to patients with chronic constipation,” the authors concluded.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.
